单位:[1]Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China[2]Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing 100700, China[3]Beijing University of Chinese Medicine, Beijing 100029, China[4]China-Japan Friendship Hospital, Beijing 100029, China[5]Guang’an men Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China[6]Department of Internal Neurology, First Affiliated Hospital, Guangxi University of Chinese Medicine, Guangxi 530000, China
Intracerebral hemorrhage (ICH) is a severe, life-threatening subtype of stoke that constitutes a crucial health and socioeconomic problem worldwide. However, the current clinical treatment can only reduce the mortality of patients to a certain extent, but cannot ameliorate neurological dysfunction and has a high recurrence rate. Increasing evidence has demonstrated that mitochondrial dysfunction occurs in the early stages of brain injury and participates in all stages of secondary brain injury (SBI) after ICH. As the energy source of cells, various pathobiological processes that lead to SBI closely interact with the mitochondria, such as oxidative stress, calcium overload, and neuronal injury. In this review, we discussed the structure and function of mitochondria and the abnormal morphological changes after ICH. In addition, we discussed recent research on the involvement of mitochondrial dynamics in the pathological process of SBI after ICH and introduced the pathological variations and related molecular mechanisms of mitochondrial dysfunction in the occurrence of brain injury. Finally, we summarized the latest progress in mitochondrion-targeted agents for ICH, which provides a direction for the development of emerging therapeutic strategies targeting the mitochondria after ICH.
基金:
National Key R&D Program of China [2018YFC1705005]
语种:
外文
WOS:
中科院(CAS)分区:
出版当年[2021]版:
大类|2 区医学
小类|1 区药学2 区医学:研究与实验
最新[2025]版:
大类|2 区医学
小类|2 区医学:研究与实验2 区药学
JCR分区:
出版当年[2020]版:
Q1PHARMACOLOGY & PHARMACYQ1MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
第一作者单位:[1]Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China[2]Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing 100700, China[3]Beijing University of Chinese Medicine, Beijing 100029, China
共同第一作者:
通讯作者:
通讯机构:[1]Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China[2]Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing 100700, China[5]Guang’an men Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China[*1]Guang’an men Hospital, China Academy of Chinese Medical Sciences, Beijing, China[*2]Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
推荐引用方式(GB/T 7714):
Li Yuanyuan,Liu Haoqi,Tian Chao,et al.Targeting the multifaceted roles of mitochondria in intracerebral hemorrhage and therapeutic prospects[J].BIOMEDICINE & PHARMACOTHERAPY.2022,148:doi:10.1016/j.biopha.2022.112749.
APA:
Li, Yuanyuan,Liu, Haoqi,Tian, Chao,An, Na,Song, Ke...&Gao, Yonghong.(2022).Targeting the multifaceted roles of mitochondria in intracerebral hemorrhage and therapeutic prospects.BIOMEDICINE & PHARMACOTHERAPY,148,
MLA:
Li, Yuanyuan,et al."Targeting the multifaceted roles of mitochondria in intracerebral hemorrhage and therapeutic prospects".BIOMEDICINE & PHARMACOTHERAPY 148.(2022)